Proof-of-concept studies ongoing in lupus nephritis (LN), systemic sclerosis (SSc) and antibody mediated rejection (AMR); topline results expected for LN in fourth quarter of 2025, SSc in second half ...

Asian shares are mixed after most U.S. stocks slipped, as doubts rose on Wall Street about whether the Federal Reserve will ...

We are well positioned for growth in the second half of 2025, supported by the ramp‑up of large contracts, increased UK spending, and improved market stability.